For virologically suppressed adults with HIV-1. See Full Indication.

Safety of CABENUVA

The safety and tolerability of CABENUVA have been studied in a robust clinical trial program: ATLAS, FLAIR, and ATLAS-2M. Use the links below to review the safety profiles of once-monthly (ATLAS & FLAIR) and every-2-month (ATLAS-2M) administration of CABENUVA.

Risks Icon

ATLAS & FLAIR: Once-Monthly CABENUVA

View the potential adverse reactions of once-monthly CABENUVA as observed in ATLAS & FLAIR, including treatment-related adverse reactions and discontinuation rates due to adverse reactions

Risks Icon

ATLAS-2M: Every-2-Month CABENUVA

View the potential adverse reactions of once-monthly CABENUVA as observed in ATLAS-2M, including treatment-related adverse reactions and discontinuation rates due to adverse reactions

CBRWCNT210052